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Background: Stress of the endoplasmic reticulum (ER) leading to activation of the unfolded protein response (UPR)
and alveolar epithelial cell (AEC) apoptosis may play a role in the pathogenesis of idiopathic pulmonary fibrosis
(IPF). Our objectives were to determine whether circulating caspase-cleaved cytokeratin-18 (cCK-18) is a marker of
AEC apoptosis in IPF, define the relationship of cCK-18 with activation of the UPR, and assess its utility as a
diagnostic biomarker.
Methods: IPF and normal lung tissues were stained with the antibody (M30) that specifically binds cCK-18. The
relationship between markers of the UPR and cCK-18 was determined in AECs exposed in vitro to thapsigargin to
induce ER stress. cCK-18 was measured in serum from subjects with IPF, hypersensitivity pneumonitis (HP),
nonspecific interstitial pneumonia (NSIP), and control subjects.
Results: cCK-18 immunoreactivity was present in AECs of IPF lung, but not in control subjects. Markers of the UPR
(phosphorylated IRE-1α and spliced XBP-1) were more highly expressed in IPF type II AECs than in normal type II
AECs. Phosphorylated IRE-1α and cCK-18 increased following thapsigargin-induced ER stress. Serum cCK-18 level
distinguished IPF from diseased and control subjects. Serum cCK-18 was not associated with disease severity or
outcome.
Conclusions: cCK-18 may be a marker of AEC apoptosis and UPR activation in patients with IPF. Circulating levels
of cCK-18 are increased in patients with IPF and cCK-18 may be a useful diagnostic biomarker.
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Idiopathic pulmonary fibrosis (IPF) is a progressive
interstitial lung disease (ILD) with no established
pharmacotherapy and a median survival of 3 years [1,2].
Due to incompletely understood pathophysiology and
the lack of mechanistic biomarkers, drug development
and testing in IPF typically relies on relatively insensitive
clinical measures such as change in pulmonary function
or survival time. Identification of mechanistically in-
formative biomarkers of specific pathologic processes* Correspondence: paul.wolters@ucsf.edu
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reproduction in any medium, provided the ormay allow for faster, cheaper, and safer development and
testing of candidate drugs.
Several studies have implicated type II alveolar epithe-
lial cell (AEC) injury and death in the pathogenesis of
IPF [3-7]. In some instances, epithelial cell death is
programmable, as AEC apoptosis has been demonstrated
in patients with IPF [3-5]. Proposed causes of AEC
apoptosis in IPF include oxidative stress and DNA dam-
age, [8] TGF-β and Fas ligand, [9] and stress of the
endoplasmic reticulum (ER). ER stress occurs when
there is an imbalance between cellular demand for pro-
tein synthesis by the ER and the ER’s capacity to
synthesize, process and package the requisite proteins
[5,6]. When under stress, the ER attempts to maintain
homeostasis by activating the unfolded protein response. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stasis, it sacrifices the cell by activating apoptotic path-
ways [11]. Markers of the UPR and apoptosis are
increased in lung tissue from patients with IPF and
localize to the alveolar epithelium [5,6]. These observa-
tions suggest ER stress and activation of the UPR may
be one trigger of AEC apoptosis in IPF patients.
Cytokeratin-18 is a cytoskeletal protein that is primar-
ily found in pseudostratified and simple epithelia, includ-
ing the alveolar epithelium [12]. During apoptosis of
epithelial cells, cytokeratin-18 is cleaved twice by cas-
pases, generating an 18-kilodalton fragment termed
caspase-cleaved cytokeratin-18 (cCK-18). This caspase-
specific processing exposes a neo-epitope at the c-
terminal end of cCK-18 that is recognized by a specific
monoclonal antibody (M30) [13]. The overall objective
of this study was to use the M30 antibody to define
whether there is a relationship between activation of the
UPR and formation of cCK-18 in lung AECs, and to de-
termine whether circulating cCK-18 could serve as a
mechanistic biomarker of the UPR and AEC apoptosis
in IPF.
Methods
Type II alveolar epithelial cell isolation and induction of
ER Stress
Type II AECs were isolated from explanted IPF lungs
and unused donor lungs (procured from the Northern
California Transplant Donor Network) as previously
described [14]. Purity of human alveolar type II cells,
assessed by pro-surfactant protein C (SPC) staining on
cytospin, was > 95% for IPF and normal lungs. The diag-
nosis of IPF was confirmed in all cases by multidisciplin-
ary review according to established criteria [15,16]. A549
cells were obtained from the American Type Culture
Collection (Manassas, VA, USA). Cells were exposed to
thapsigargin (EMD Chemicals, Inc., Gibbstown, NJ,
USA) for varying lengths of time to induce ER stress.
Lung tissue preparation and immunohistochemistry for
cCK-18
For immunohistochemistry, IPF lung tissue was obtained
from the Tissue Core Laboratory of the Lung Tissue Re-
search Consortium (Denver, CO). Healthy normal lung
tissue was procured from lungs not used by the North-
ern California Transplant Donor Network. Briefly, en-
dogenous peroxidase was inhibited in 5-μm tissue
sections by incubating the sections in 3% hydrogen per-
oxide for 30 minutes. After washing with PBS, the sec-
tions were incubated for one hour in PBS containing 5%
normal goat serum and 1% bovine serum albumin
(BSA), then incubated with a 1:500 dilution of monoclo-
nal mouse anti-cCK18 antibody (M30 antibody, M30
CytoDEATH, PEVIVA, Bromma, Sweden) overnight at4°C. The sections were washed in 0.1% PBS-Tween 20,
incubated for 40 minutes with horseradish peroxidase
(HRP)-conjugated goat anti-mouse IgG (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). After washing, the
bound peroxidase activity was detected using a diamino-
benzidine (DAB) substrate kit (Vector Laboratories,
Burlingame, CA, USA). The sections were then washed
in deionized water and counterstained with Meyer’s
hematoxylin (Sigma-Aldrich). For each tissue, an adja-
cent section was stained only with secondary antibody
to address nonspecific binding of the secondary
antibody.
FACS Sorting
Epithelial cells were suspended in DME H-21 containing
10% fetal bovine serum and incubated for 30 minutes on
ice with antibodies to Annexin V (BD Biosciences, San
Jose CA) per the manufacturer’s protocol. Samples were
then analyzed using a LRS II flow cytometer (Becton
Dickinson) and sorted into Annexin V + or - popula-
tions using a Moflo High Performance Cell Sorter (Dako
Cymation).
Immunoblots
Cell lysates were subjected to SDS-PAGE under redu-
cing conditions and transferred to nitrocellulose mem-
brane (Life Sciences Products, Boston, MA). The
membrane was washed with 50 mM Tris–HCl contain-
ing 0.5 M NaCl, 0.01% Tween-20, (TBS; pH 7.5) and
incubated overnight in 5% milk containing primary anti-
body. The membrane was then washed with TBS, incu-
bated in TBS for 30 min containing a 1:2,000 dilution of
HRP-conjugated secondary antibody (New England Bio-
labs, Beverly, MA) and washed again. Immunoreactivity
was detected using the phototope-HRP-detection kit
(New England Biolabs). Primary antibodies included:
mouse anti-human cCK-18 (1:1000, M30), rabbit-anti
human IRE-1α (1:1000 Novus Biologicals, Littleton, CO,
USA), rabbit-anti human phospho-specific IRE-1α
(1:2000, Novus Biologicals), and mouse anti-human β-
actin (1:1000, Sigma-Aldrich).
XBP-1 mRNA splicing
Total RNA from type II AECs and A549 cells was
extracted using a standard Trizol (Invitrogen, Carlsbad,
CA) protocol. cDNA was synthesized from total RNA
using One-Step RT-PCR SuperScript III reverse tran-
scriptase (Invitrogen) per the manufacturer’s protocol.
XBP-1 splicing was quantified by PCR using methods
described previously [17]. Sense primer mXBP1.3S (5’-
AAACAGAGTAGCAGCGCAGACTGC-3’) and anti-
sense primer mXBP1.2AS (5’- GGATCTCTAAAACTA
GAGGCTTGGTG-3’) were used. PCR fragments were
digested by PstI. The PstI cleavage site is located in the
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ation between the unspliced XBP-1 amplicon (cut PCR
product) and the spliced XBP-1 amplicon. PCR products
were resolved on 2% agarose gels, stained with EtBr, and
quantified by densitometry. XBP1-specific primers were
synthesized by Integrated DNA Technologies Inc (Coral-
ville, IA, USA). The PCR fragments were visualized with
BioDoc-It Imaging System (UVP, Inc., Upland, CA,
USA).
Blood and BAL ELISA for cCK-18
Blood samples, clinical information, and survival data
from patients with IPF, chronic hypersensitivity pneu-
monitis (HP), and nonspecific interstitial pneumonitis
(NSIP) enrolled in an on-going longitudinal research co-
hort were collected at the time of initial presentation to
UCSF. All ILD diagnoses were established thorough
multidisciplinary review of clinical data, radiology, and
pathology according to established criteria[15,16,18,19].
Patients with chronic HP required either a diagnostic
surgical lung biopsy, or a compatible HRCT combined
with a chronic and high-intensity exposure (e.g. living
with a pet bird, living or working on a farm). Patients
with NSIP were defined according to previously pub-
lished criteria [20]. Bronchoalveolar lavage (BAL) sam-
ples were obtained for research purposes in a subset of
IPF subjects. A second cohort consisted of blood sam-
ples from stable IPF and acute exacerbation of IPF
patients seen at Asan Medical Center, University of
Ulsan (Seoul, South Korea) [21]. Stable IPF patients were
defined as outpatients with IPF who were not experien-
cing a rapid decline in respiratory function. Acute ex-
acerbation of IPF was diagnosed using consensus criteria
[22]. Written informed consent was obtained from all
patients according to institutional review board-
approved protocols. In all samples, M30 reactivity was
measured using a commercially available ELISA (M30-
Apoptosense ELISA, PEVIVA, Bromma, Sweden) accord-
ing to the manufacturer’s protocol.
Statistical analysis
Serum cCK-18 levels were compared between IPF and
control groups using the Wilcoxon rank-sum test. The
association of cCK-18 level with the diagnosis of IPF was
tested for confounding by age, gender, smoking history,
dyspnea severity, the use of long-term supplemental oxy-
gen therapy, baseline FVC, and baseline DLCO using re-
gression analysis. The ability of serum cCK-18 level to
predict disease progression in the UCSF cohort was
tested using a Wilcoxon rank-sum test. Disease progres-
sion was indicated as previously defined by our group:
10% decline in FVC, 15% decline in DLCO, lung trans-
plantation, or death due to any cause within 6 months of
the blood draw [23]. Multivariate Cox proportionalhazards analysis was used to evaluate the relationship of
cCK-18 with transplant-free survival. All analyses were
repeated using a dichotomous cCK-18 variable. All data
analysis was performed using STATA 11.0 (StataCorp,
Texas, USA).
Results
The UPR is activated in type II alveolar epithelial cells
isolated from IPF lung
It has been reported that the UPR is activated in the epi-
thelial cells of IPF patients. To confirm these observa-
tions, the relative levels of phospho-IRE-1α, and XBP-1
mRNA splicing were measured in AECs isolated from
normal and IPF lungs. Type II AECs of IPF lungs
expressed more total IRE-1α compared to normal lungs
and the phosphorylated form was detected in type II
AECs of IPF, but not in normal lungs (Figure 1A). There
was also more spliced XBP-1 in type II AECs of IPF
lungs compared to normal lungs (p = 0.0495; Figure 1B).
These findings demonstrate that the UPR pathway is
activated in type II AECs isolated from IPF patients.
ER stress triggers cCK-18 formation in cultured alveolar
epithelial cells
Because ER stress and subsequent activation of the UPR
can lead to apoptosis, [11] we next examined whether
induction of ER stress leads to the formation of cCK-18.
To do this, A549 cells were exposed to thapsigargin, an
inducer of ER stress, for varying lengths of time. Phos-
phorylated IRE-1α expression increased following thapsi-
gargin exposure (Figure 2A), confirming that thapsigargin
activated the UPR in AECs. cCK-18 increased in
thapsigargin-exposed A549 cells (Figure 2A), demonstrat-
ing that activation of the UPR can lead to formation of
cCK-18 in AECs.
cCK-18 is formed prior to the appearance of the
apoptosis marker Annexin V
Next we measured the appearance of thapsigargin-
mediated cCK-18 formation in relationship to annexin
V, an early marker of apoptosis. Thapsigargin-exposed
A549 cells were harvested and separated into two popu-
lations (annexin V + or –) by flow sorting for the cell
surface expression of annexin V. Figure 2B shows that
cCK-18 first appears in annexin V– cells 48 hrs after
thapsigargin exposure, and remains present in annexin
V– cells 72 hrs after thapsigargin, when it begins to ap-
pear in annexin V+ cells.
cCK-18 is present in the alveolar epithelium of IPF lung
Activation of the UPR and apoptosis have been reported
in AECs of IPF lungs[5,6]. To examine whether cCK-18
formation is similarly present in IPF AECs, sections of































Figure 1 The UPR is activated in type II AECs isolated from IPF lungs. Phosphorylated IRE-1α (panel A) and spliced XBP-1 (panel B) were
present in increased amounts in AECs from 3 different IPF lungs, but not in the 3 control subjects (* P < 0.05, **P = 0.0495 by Wilcoxon rank sum
























Figure 2 cCK-18 is formed following activation of the UPR. A.
Immunoblots for phospho-IRE1 (p-IRE1), total IRE1 (IRE1), and
cleaved cytokeratin 18 (cCK-18) showing time-dependent increase of
cCK-18 in A549 cells exposed to 0.5 μM of thapsigargin (TG, +) for
various lengths of time. Immunoblots showing an increase in total
and phospho-IRE1 confirm thapsigargin activates the UPR in A549
cells compared to vehicle controls (−). B. Immunoblots for cCK-18
showing time-dependent appearance of cCK-18 in annexin V– or V+
A549 cells exposed to 0.5 μM of thapsigargin for various lengths of
time.
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cCK-18 (Figures 3A, B). In contrast, lung tissue from
control subjects was not immunoreactive for cCK-18
(Figure 3D).cCK-18 is elevated in the serum of IPF patients
cCK-18 has been reported to be a circulating biomarker
of epithelial cell apoptosis [12]. To examine whether cir-
culating cCK-18 levels are preferentially increased in
patients with IPF, cCK-18 levels were measured in the
serum of 169 subjects, including 84 subjects with IPF, 24
with HP, 22 with NSIP, and 39 control subjects. Demo-
graphic and clinical characteristics of these subjects are
summarized in Table 1. Serum cCK-18 levels were sig-
nificantly elevated in the serum of IPF patients com-
pared to control subjects (area under the receiver
operating characteristic curve (AUC) 0.88, p<0.00005)
(Figure 4A). Furthermore, serum levels of cCK-18 were
significantly different in IPF patients compared to those
in patients with HP or NSIP (AUC 0.76, p<0.00005)
(Figure 4B). There were no differences in cCK-18 level
comparing HP, NSIP, and control subjects. cCK-18 was
an independent predictor of a diagnosis of IPF versus
HP and NSIP when controlling for baseline variables
(p=0.001). The addition of cCK18 to baseline variables
significantly improved the AUC from 0.83 to 0.88




Figure 3 Immunohistochemistry of IPF and normal lung with M30 antibody. A. IPF lung immunostained with the M30 antibody (20x). B.
Higher power view of IPF lung immunostained with the M30 antibody (40x). C. IPF lung immunostained with a non-immune antibody (20x). D.
Normal lung immunostained with the M30 antibody showing an absence of staining for cCK-18 (40x). Bar = 50 μm. Images are representative of
staining of tissue from 8 patients with IPF and 8 control subjects.
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variables or outcomes
Serum cCK-18 level was not associated with any baseline
clinical variables. Further, serum cCK-18 level did not
predict progression measured by a change in FVC,Table 1 Subject characteristics of UCSF cohort
Variable IPF
(n = 84)
Age, years 70.3 (7.9)
Male sex, % 76.2
Diagnosis by surgical lung biopsy, % 50.0
Smoking history
Ever smoked, % 78.6
Pack-years 27.7 (28.7)
Measures of disease severity
Dyspnea score 9.8 (6.0)
Long-term oxygen therapy, % 20.2
Pulmonary function
FVC, % predicted 69.4 (18.2)
DLCO, % predicted 46.7 (18.4)
Data shown are mean (standard deviation), unless otherwise indicated.
* p < 0.05 for comparison with the IPF cohort.
Abbreviations: DLCO, diffusing capacity of carbon monoxide; FVC, forced vital capac
nonspecific interstitial pneumonia; UCSF, University of California San Francisco.DLCO or survival. There was no change in results with
secondary analyses that analyzed cCK-18 as a dichotom-
ous variable or that considered alternative outcome vari-
ables (i.e. considering individual pulmonary function test
variables as dichotomous or continuous variables). In aHP NSIP
(n = 24) (n = 22)




11.8 (18.8)* 6.4 (13.8)*
11.2 (4.6) 9.6 (4.4)
23.8 27.3
67.3 (22.0) 64.1 (19.1)
55.1 (21.2) 43.7 (14.4)
ity; HP, hypersensitivity pneumonitis; IPF, idiopathic pulmonary fibrosis; NSIP,
Figure 4 Serum cCK-18 levels in patients with lung fibrosis. A. Serum cCK-18 level is higher in IPF (n=84) than HP (n=24), NSIP (n=22), or
control subjects (n=39); p ≤ 0.001 for comparison of IPF with all subgroups). cCK-18 level is similar in HP, NSIP, and control subjects. B. cCK-18
distinguishes IPF from other fibrotic ILDs (area under the receiver operating characteristic curve [AUC] = 0.76). Sensitivity (Sn), specificity (Sp), and
likelihood ratios (LR) are shown for the diagnosis of IPF (versus HP and NSIP) using several cCK-18 thresholds. A cut-off of 115 units per liter
(dashed line) provided the highest AUC (0.76). * Four outliers are excluded from the IPF group for illustrative purposes (cCK-18 values not shown:
433, 513, 979, 1147 units/L).
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increased during acute exacerbation of IPF compared to
stable disease (p = 0.15) (Figure 5).
Discussion
We have shown that markers of ER stress and the UPR
are increased in type II AECs isolated from IPF lung,
confirming that these pathways are activated in IPF
patients. We have also shown that cCK-18 is present in
IPF AECs, is generated by activation of the UPR in vitro,
and is uniquely elevated in the serum of patients with
IPF compared to normal and diseased ILD control sub-
jects. This suggests that cCK-18 may be a biomarker of
the UPR and AEC apoptosis and that it could be used to
monitor therapies modulating the UPR or AEC apop-
tosis in IPF patients.
The UPR is a mechanism by which the ER attempts to
maintain homeostasis when exposed to proteins that are
unfolded or folded incorrectly [10]. Initially, the UPR
attempts to restore homeostasis within the ER. Failure
to restore homeostasis via the UPR leads to apoptosis
[11]. Previous studies have shown that the UPR is acti-
vated in the alveolar epithelium of human IPF lung [5,6].
We build upon these data by directly confirming that
the UPR is activated in IPF AECs and that circulating
levels of cCK-18, a cleavage product of cytokeratin 18
formed during the UPR, is elevated in IPF patients.
A mechanistically informative biomarker should reflect
the activity of important biological pathways. Previous
biomarker studies in IPF have focused more on measur-
ing levels of proteins that predict prognosis rather thanmeasuring proteins whose levels are predictive of spe-
cific pathologic processes; examples include surfactant
protein-A and-D (SP-A and SP-D), [24-26] MMP7,
[27,28] and Krebs von den Lungen 6 antigen (KL-6),
[29,30]. CC-chemokine ligand 18 (CCL18) is an add-
itional biomarker that is increased in IPF serum and
bronchoalveolar lavage fluid and may predict progres-
sion[31-33]. CCL18 is a marker of alternative macro-
phage activation and stimulates collagen production in
normal lung tissue in vitro; [34,35] however a clear
mechanistic role of CCL18 in IPF has not been proven.
Unlike previous biomarkers, this study investigates the
use of cCK-18 as a marker of the UPR and apoptosis in
IPF patients, two pathologic processes that are activated
in IPF patients [4-6]. cCK-18 is generated by caspases
activated during apoptosis of epithelial cells, [12] sug-
gesting it is a marker for AEC apoptosis in patients with
IPF. In addition, new data in this manuscript (Figure 2)
show that cCK-18 is formed following activation of the
UPR in lung epithelial cells. These findings suggest that
cCK-18 may be a marker for apoptosis or the UPR in
IPF patients.
Circulating cCK-18 does not distinguish between acti-
vation of the UPR and apoptosis in epithelial cells.
Nevertheless, data in Figure 2B demonstrate that epithe-
lial cells generate cCK-18 following activation of the
UPR yet before expression of the apoptosis marker
annexin V. This suggests cCK-18 may be generated in
cells containing levels of active caspase that are insuffi-
cient to activate apoptosis, but sufficient to cleave cyto-
keratin 18. Because the number of alveolar epithelial
Figure 5 Serum cCK-18 is not increased during acute
exacerbation of IPF. Serum cCK-18 levels were measured in the
serum of 34 patients with stable IPF and 36 different patients
suffering from an acute exacerbation of IPF.
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active caspase 3 [8] are far greater than the rare TUNEL
positive alveolar epithelial cell found in IPF lungs (data
not shown), this is the most likely scenario in IPF lung.
Proving this will require future identification of more
specific biomarkers of the UPR that can be correlated to
cCK-18.
We show that cCK-18 could also be a useful diagnostic
biomarker that distinguishes IPF from chronic HP and
NSIP, independent of age, gender, smoking, disease se-
verity, and other baseline variables. A recent small study
found that cCK-18 may also be elevated in the serum ofpatients with organizing pneumonia [36]. The clinical
importance of this finding is uncertain, given that IPF
and organizing pneumonia have unique clinical and
radiological features [19]. We used chronic HP and idio-
pathic fibrotic NSIP as disease controls because the clin-
ical, radiologic, and pathologic features of chronic HP
and fibrotic NSIP often have substantial overlap with
IPF [15,16,18,19]. Distinguishing IPF from HP and NSIP
often requires a surgical lung biopsy, a procedure that
carries substantial risk [15,16]. If confirmed in other
cohorts, a serum biomarker, such as cCK-18, that distin-
guishes IPF from other fibrotic ILDs may reduce the
need for lung biopsy.
Serum cCK-18 was not associated with severity or pro-
gression of IPF. This conflicts with a previous study that
showed cCK-18 correlated with physiologic measures in
patients with a variety of ILDs [36]. Several possibilities
could explain the lack of association seen our study.
First, cCK-18 was measured at a single time point. This
single measurement may not be representative of activa-
tion of the UPR or apoptosis over the course of an indi-
vidual’s disease. Second, circulating levels of cCK-18
likely reflect the sum of a complex interplay of physio-
logical processes (i.e. production, clearance, metabolism),
each of which may impact the cCK-18 level differently in
individual patients. In addition, physiologic progression
was measured over a time interval of 6-months after
cCK-18 measurement, and cCK-18 level might reflect
disease activity and progression on a more limited time
scale (e.g. days or weeks). Third, although data were
adjusted for several clinical and physiologic variables,
other confounders may have been present, including oc-
cult conditions, unrelated to IPF, that could cause apop-
tosis of AECs. cCK-18 was also not elevated in the
serum of patients during acute exacerbation of IPF. This
may suggest that AEC apoptosis is not a prominent fea-
ture of acute exacerbation, however this finding requires
further study as there was a trend for higher serum
levels of cCK-18 in patients during acute exacerbation of
IPF. Finally, we also were unable to detect cCK-18 in
BAL fluid in patients with IPF. The reason for this is un-
known, but may relate to dilution that occurs during the
BAL procedure or to different metabolism of cCK-18 in
the alveoli compared to the serum.
Conclusions
In summary, data reported in this manuscript show that
the UPR is activated in AECs of IPF patients and that
cCK-18 may be a marker of this process. This finding
suggests that cCK-18 could be used in the early-phase
development of drugs targeting the UPR in IPF patients.
In addition, serum cCK-18 levels may be clinically in-
formative as a diagnostic marker of IPF. Further research
measuring serial cCK-18 levels in a longitudinal cohort
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determine the impact of temporal changes in serum
cCK-18 on its performance as a measure of disease ac-
tivity and course.
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